Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN185619 - Provider product page
- Provider
- antibodies-online
- Proper citation
- Antibodies-Online Cat#ABIN185619, RRID:AB_10782831
- Product name
- anti-Tuberous Sclerosis 1 (TSC1) (C-Term) antibody
- Antibody type
- Polyclonal
- Description
- Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
- Reactivity
- Human
- Host
- Goat
- Epitope
- C-Term
- Vial size
- 100 μg
- Storage
- Aliquot and store at -20°C.
- Handling
- Minimize freezing and thawing.
Submitted references Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors.
Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase.
Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP
Proceedings of the National Academy of Sciences of the United States of America 2005 Jan 18;102(3):667-72
Proceedings of the National Academy of Sciences of the United States of America 2005 Jan 18;102(3):667-72
Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ
Journal of neuropathology and experimental neurology 2004 Dec;63(12):1236-42
Journal of neuropathology and experimental neurology 2004 Dec;63(12):1236-42
TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase.
Goncharova E, Goncharov D, Noonan D, Krymskaya VP
The Journal of cell biology 2004 Dec 20;167(6):1171-82
The Journal of cell biology 2004 Dec 20;167(6):1171-82
No comments: Submit comment
No validations: Submit validation data